Editor’s Note As the U.S. innovation engine enters 2025, FDA CDER data tell a clear story: R&D growth is no longer about volume—it’s about focus. While IND filings continue to rise, the real action is shifting toward biologics, cell and gene therapies, and rare disease programs that demand deeper regulatory engagement. This issue unpacks the [...]